Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, Novo Nordisk and Wegovy
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for those manufacturers to make safely.
Novo Nordisk asks FDA to ban cheap copies of Wegovy, Ozempic, CNBC reports
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks,
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited amounts, and have been reaping the rewards of supplying versions of Novo Nordisk's obesity drug Wegovy and Ozempic for diabetes, which are both based on the GLP-1 receptor agonist.
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs
Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight loss and diabetes medications.
Novo Makes Case to FDA That Semaglutide Is Too Complex for Compounders to Produce
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which includes drugs that are too complicated to produce and could pose substantial safety risks to patients if manufactured incorrectly.
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable Difficulties for Compounding Lists."
Novo seeks to block compounders' Ozempic copies
Novo Nordisk is pushing the FDA to block compounders from making copies of its Ozempic and Wegovy, saying the weight-loss treatments are too complex to safely replicate. Why it matters: It's the latest twist in the battle between pharma giants and compounders over the law that allows copies of patent-protected drugs amid shortages.
23h
on MSN
Novo Nordisk Lashes Out at Wegovy Copycats. What it Means for Hims & Hers.
The Danish drugmaker asked the agency to put semaglutide, the active ingredient in Wegovy and Ozempic, on a list of drugs ...
FiercePharma
1d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants
Novo
...
ENDPOINTS NEWS
4h
Novo Nordisk petitions FDA to stop semaglutide compounding over safety risks
Novo Nordisk is continuing its crusade against compounded versions of its blockbuster weight loss drugs by petitioning the ...
BioSpace
40m
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback